Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 4/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.42 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 7/20 | 0.37 |
| ▸ | CES1 | P23141 | 5/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5267236 | 1.00 | EPHX1 (0.44) | EPHX1PLA2G2CPLA2G2AZDHHC7USP2 | |
| SCHEMBL16575957 | 0.84 | EPHX1 (0.45) | EPHX1PLA2G2CPLA2G2AFAAHCES1 | |
| SCHEMBL17972439 | 0.82 | EPHX1 (0.51) | EPHX1PLA2G2CFAAHCES1CES2 | |
| SCHEMBL18349797 | 0.81 | PLA2G2A (0.42) | EPHX1PLA2G2CPLA2G2ALMNAMEN1 | |
| SCHEMBL18349791 | 0.81 | PLA2G2C (0.42) | EPHX1PLA2G2CPLA2G2ALMNAMEN1 | |
| SCHEMBL16574363 | 0.81 | PLA2G2A (0.55) | PLA2G2A | |
| SCHEMBL15942203 | 0.80 | EPHX1 (0.50) | EPHX1PLA2G2CLMNAFAAHCES1 | |
| SCHEMBL15948722 | 0.80 | EPHX1 (0.50) | EPHX1PLA2G2CLMNAFAAHCES1 | |
| SCHEMBL18349792 | 0.79 | EPHX1 (0.47) | EPHX1PLA2G2CLMNAFAAHCES1 | |
| SCHEMBL16575605 | 0.78 | PLA2G2A (0.73) | EPHX1PLA2G2CPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1287006-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2007-10-24 | — | — | EP | disclosed |
| US-7138547-B2 | Antitumoral compounds | PHARMA MAR, S.A. | 2006-11-21 | — | — | US | disclosed |
| US-20040048834-A1 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048834-A1 | Antitumoral compounds | HCCS, MSR1, SUCNR1 | EPHX1 3121/4885PLA2G2C 3712/4885PLA2G2A 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.